Evolution of Acute Pulmonary Embolism Management
Acute pulmonary embolism (PE) remains a significant cause of cardiovascular morbidity and mortality worldwide. Historically, management strategies were largely binary: systemic anticoagulation for hemodynamically stable patients and systemic thrombolysis or surgical embolectomy for those with massive, life-threatening obstructions. However, the emergence of the ‘intermediate-risk’ or ‘submassive’ PE category has created a clinical gray area where the risks of systemic thrombolysis—most notably intracranial hemorrhage—often outweigh the perceived benefits. This clinical challenge necessitated a more nuanced approach, leading to the development of Multidisciplinary Pulmonary Embolism Response Teams (PERT) and a burgeoning interest in catheter-directed therapies (CDT).
As these specialized teams have become more prevalent, the landscape of PE treatment has shifted. Clinicians are now equipped with a diverse array of interventional tools, ranging from ultrasound-assisted thrombolysis to large-bore mechanical thrombectomy. Despite this rapid technological expansion, real-world data on how these treatments are being utilized and their subsequent impact on patient outcomes compared to standard care have been limited. The recent analysis of the PERT Consortium registry provides essential insights into these trends and the clinical efficacy of a multidisciplinary, interventional approach.
